THE MTOR PATHWAY ACTIVATION PREDICTS A SHORT TIME TO PROGRESSION AND OVERALL SURVIVAL IN RELAPSED MULTIPLE MYELOMA PATIENTS

被引：0
|
作者：
Guglielmelli, T. [1 ]
Merlini, R. [1 ]
Giugliano, E. [1 ]
Saglio, G. [1 ]
Brunetto, V. [1 ]
Cappia, S. [1 ]
Bacillo, E. [1 ]
Berruti, A. [1 ]
Gay, F. [2 ]
Papotti, M. [1 ]
Palumbo, A. [2 ]
机构：
[1] AUO San Luigi Gonzaga, Orbassano, Italy
[2] ASO S Giovanni Battista Osp Molinette, Turin, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0369
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [31] Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint
    Rosenberg, Aaron Seth
    Facon, Thierry
    Abouzaid, Safiya
    Srinivasan, Shankar
    Chung, Weiyuan
    Parikh, Kejal
    Tuscano, Joseph
    BLOOD, 2017, 130
  • [32] Pomalidomide Monotherapy for Relapsed Myeloma Is Associated with Excellent Responses and Prolonged Progression Free and Overall Survival
    Streetly, Matthew
    Stewart, Orla
    Gyertson, Kylie
    Kazmi, Majid A.
    Schey, Steve
    BLOOD, 2009, 114 (22) : 1492 - 1492
  • [33] MEASURING AND ANALYSING THE MATURITY OF OVERALL SURVIVAL DATA FOR TREATMENTS FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Monnickendam, G.
    Zhang, L.
    Quinn, C.
    VALUE IN HEALTH, 2018, 21 : S363 - S363
  • [34] Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
    Song, Ga-Young
    Jung, Sung-Hoon
    Kim, Kihyun
    Kim, Seok Jin
    Yoon, Sang Eun
    Lee, Ho Sup
    Kim, Mihee
    Ahn, Seo-Yeon
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BMC CANCER, 2020, 20 (01)
  • [35] Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma
    Ga-Young Song
    Sung-Hoon Jung
    Kihyun Kim
    Seok Jin Kim
    Sang Eun Yoon
    Ho Sup Lee
    Mihee Kim
    Seo-Yeon Ahn
    Jae-Sook Ahn
    Deok-Hwan Yang
    Hyeoung-Joon Kim
    Je-Jung Lee
    BMC Cancer, 20
  • [36] Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma
    Weber, Donna
    Knight, Robert
    Chen, Christine
    Spencer, Andrew
    Yu, Zhinuan
    Zeldis, Jerome
    Olesnyckyj, Marta
    Dimopoulos, Meletios
    BLOOD, 2007, 110 (11) : 128A - 128A
  • [37] Effect of a second autograft of hematopoietic stem cells on the overall survival in relapsed multiple myeloma
    Cecile, Gruchet
    Guidez, Stephanie
    Cayssials, Emilie
    Xavier, Leleu
    HEMATOLOGIE, 2016, 22 (04): : 249 - +
  • [38] Bortezomib produces survival advantage in relapsed multiple myeloma patients
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (08): : 1028 - 1028
  • [39] Immune Suppression By High-Density Neutrophils Predicts Short Progression-Free Survival in Multiple Myeloma
    Romano, Alessandra
    Manteiga, Jose
    Simeon, Vittorio
    Parrinello, Nunziatina L.
    Giallongo, Cesarina
    La Cava, Piera
    Conticello, Concetta
    Tibullo, Daniele
    Fontana, Francesca
    Ciceri, Fabio
    Cremasco, Floriana
    Fabbri, Monica
    Musto, Pellegrino
    Cenci, Simone
    Di Raimondo, Francesco
    BLOOD, 2016, 128 (22)
  • [40] P53 Pathway Activation Mediated High c-MAF Expression Is Associated with Overall and Post-Progression Survival in Multiple Myeloma
    Yamane, Eiko
    Oda, Tsukasa
    Sunaga, Masanobu
    Murakami, Yuki
    Ishihara, Rei
    Asao, Yuta
    Masuda, Yuta
    Watanabe, Saki
    Kobayashi, Nobuhiko
    Takei, Hisashi
    Osaki, Yohei
    Nanami, Gotoh
    Kasamatsu, Tetsuhiro
    Shimizu, Hiroaki
    Ishizaki, Takuma
    Koiso, Hiromi
    Takizawa, Makiko
    Ogawa, Yoshiyuki
    Yokohama, Akihiko
    Tsukamoto, Norifumi
    Saitoh, Takayuki
    Murakami, Hirokazu
    Handa, Hiroshi
    BLOOD, 2019, 134
12345